Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,057 questions · 1,077 findings · 32 reviews · Skin

No studies found 395 · 36.7%GRADE not reported 89 · 8.3%Very low 172 · 16%Low 177 · 16.4%Moderate 191 · 17.7%High 53 · 4.9%

Etretinate vs PUVA

Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Etretinate vs PUVA

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Etretinate vs PUVA

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

It is very uncertain whether etretinate changes proportion of participants with adverse effects ‐ measured over 12… compared with PUVA therapy (very low certainty).

1 finding from 1 review

Etretinate vs PUVA

Ease of compliance to an intervention or a treatment ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants achieving a 50% reduction in disease severity · chronic palmoplantar pustulosis

Alitretinoin showed no clear difference in proportion of participants achieving a 50% reduction in disease… compared with placebo (moderate certainty).

1 finding from 1 review

Alitretinoin vs placebo

Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis

Alitretinoin showed no clear difference in proportion of participants with adverse effects ‐ measured over 24… compared with placebo (moderate certainty).

1 finding from 1 review

Etanercept vs placebo

Proportion of participants cleared or almost cleared ‐ · chronic palmoplantar pustulosis

Etanercept showed no clear difference in proportion of participants cleared or almost cleared in the short… compared with placebo (low certainty).

1 finding from 1 review

Etanercept vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Etanercept vs placebo

Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Etanercept vs placebo

Proportion of participants achieving a 50% reduction in disease severity ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Etanercept vs placebo

Proportion of participants without relapse in the long term ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review

Ustekinumab vs placebo

Proportion of participants with adverse effects serious or severe enough to have caused withdrawal ‐ not reported · chronic palmoplantar pustulosis

The review found no eligible studies for this question.

1 finding from 1 review